This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $7.87, marking a +2.61% move from the previous day.
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
by Debanjana Dey
HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?
by Debanjana Dey
HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.
Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Teladoc (TDOC) stood at $7.49, denoting a -3.97% move from the preceding trading day.
Why Is Teladoc (TDOC) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hims & Hers Scales Growth Through Subscriptions and Care Expansion
by Debanjana Dey
HIMS fuels growth through subscriptions, expanding care offerings and building proprietary health infrastructure at scale.
Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?
by Debanjana Dey
HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
by Debanjana Dey
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
by Zacks Equity Research
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Teladoc (TDOC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teladoc (TDOC) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of +29.63% and +1.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now?
by Debanjana Dey
Hims & Hers and Teladoc Health are reshaping virtual care, but which has the edge in earnings growth and strategic expansion? Let's see.
CVS Health (CVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Hims & Hers Health, Teladoc Health and American Well
by Zacks Equity Research
HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.
Hims & Hers Paves the Way for Global Digital Health Expansion
by Debanjana Dey
HIMS accelerates its global push with the ZAVA acquisition and a planned Canada launch targeting affordable obesity care.
Teladoc (TDOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
by Indrajit Bandyopadhyay
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $8.04, marking a +2.03% move from the previous day.
Hims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?
by Debanjana Dey
HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.
Teladoc (TDOC) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $8.32, marking a -5.56% move from the previous day.
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
by Zacks Equity Research
HIMS taps AI and $870 million in funding to deliver smarter, more personalized healthcare through tech-driven innovation.
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
by Indrajit Bandyopadhyay
OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.
Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Teladoc (TDOC) concluded the recent trading session at $8.58, signifying a -1.49% move from its prior day's close.
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
by Debanjana Dey
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.